Seikagaku Corp. | Ownership
Companies that own Seikagaku Corp.
Invesco Asset Management (Japan) Ltd.
4,804,000
8.46%
0
1.54%
03/31/2017
TIAA-CREF Investment Management LLC
1,066,800
1.88%
-20,000
0.01%
03/31/2018
The Vanguard Group, Inc.
889,588
1.57%
200
0%
07/31/2018
Nomura Asset Management Co., Ltd.
659,998
1.15%
10,099
0.01%
07/31/2018
Norges Bank Investment Management
585,199
1.03%
92,699
0%
12/31/2017
BlackRock Fund Advisors
422,500
0.74%
0
0%
09/06/2018
Nikko Asset Management Co., Ltd.
372,198
0.66%
-133,101
0%
08/20/2018
Daiwa Asset Management Co. Ltd.
315,400
0.56%
3,000
0.01%
07/31/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
258,900
0.46%
174,500
0.01%
04/09/2018
Dimensional Fund Advisors LP
184,700
0.33%
150,200
0%
04/30/2018
| Address |
Marunouchi Center Building, 10/F
Tokyo Tokyo 100
Japan
|
|
Employees
|
- |
| Website |
http://www.seikagaku.co.jp |
| Updated |
07/08/2019 |
| Seikagaku Corp. engages in the manufacture and sale of pharmaceuticals and medical devices specifically related to glycoconjugates. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. |
